DAY 3: Tuesday, September 23, 2025
Program subject to change.
07:00 - 18:00
Registration Open
07:15 - 18:15
Industry-Sponsored Symposia with Breakfast
08:30 - 09:30
Plenary Lecture 2: ADME & Delivery Strategies for Oligos
10:00 - 12:00
Concurrent Symposia 5 & 6
Symposium 5: DMPK Challenges with Targeted Genetic Medicines: Exploring the New Frontiers of Oligonucleotide Therapeutics
Co-chairs: Everett Perkins, Eli Lilly, USA; Asami Toshima, University of Shizuoka, Japan
-
This symposium will review unique challenges associated with assessing and optimizing the distribution, metabolism, and PK of targeted oligonucleotide-based therapeutics. The topics in this session will provide broad perspectives on the current and future state of oligonucleotide delivery as well as technical insight into mechanisms of metabolism and biodistribution of siRNA.
Symposium 6: Impact of AI & ML in Drug Discovery & Development
Co-chairs: James Lu, Genentech, USA; Andreas Reichel, Bayer, Germany
-
This session will highlight examples of where and how artificial intelligence and, in particular, machine learning can be impactful in enhancing drug discovery and development, with talks that apply ML approaches to predicting PK and PK/PD profiles in preclinical and clinical studies, for SMOLs and BIOLs, and for the design of new modalities such as peptides, protein degraders and gene therapies.